Comparing the effectiveness of Hepa-Mertz mono therapy versus rifaximin in patients presenting with hepatic encephalopathy

被引：0
|
作者：
Doyle, J. B. M. [1 ]
McDougall, N. I. [1 ]
Cash, W. J. [1 ]
机构：
[1] Royal Victoria Hosp, Liver Unit, Belfast BT12 6BA, Antrim, North Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
32(14S161)
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 48 条
  • [31] A randomized, double-blind, clinical trial comparing lactulose, l-ornithine l-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding
    de La Tijera, F. H.
    Servin-Caamano, A. I.
    Abdo-Francis, J. M.
    Salas-Gordillo, F.
    Perez-Hernandez, J. L.
    Camacho-Aguilera, J.
    Alla, S. N.
    Jimenez-Ponce, F.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S49 - S49
  • [32] AN EXPLORATORY ANALYSIS OF THE SURVIVAL BENEFITS IN COMMERCIALLY INSURED PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE) TREATED WITH RIFAXIMIN VERSUS LACTULOSE ALONE USING US CLAIMS DATA
    Burne, R.
    Volk, M. L.
    Guerin, A.
    Shi, S.
    Joseph, G.
    Heimanson, Z.
    Ahmad, M.
    VALUE IN HEALTH, 2021, 24 : S95 - S96
  • [33] LACTULOSE WITHDRAWAL CAN POTENTIATE BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY IN PATIENTS CONTROLLED WITH RIFAXIMIN PLUS LACTULOSE THERAPY: A POST HOC ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL
    Bajaj, Jasmohan S.
    Vinay, Sundaram
    Frenette, Catherine T.
    Heimanson, Zeev
    Israel, Robert J.
    Sanyal, Arun J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1455 - S1456
  • [34] Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial
    Bajaj, Jasmohan S.
    Sundaram, Vinay
    Frenette, Catherine
    Heimanson, Zeev
    Israel, Robert J.
    Sanyal, Arun
    JOURNAL OF HEPATOLOGY, 2020, 73 : S721 - S721
  • [35] PATIENTS WITH CIRRHOSIS AND A HISTORY OF OVERT HEPATIC ENCEPHALOPATHY EXPERIENCED LOWER 6-MONTH ALL-CAUSE MORTALITY RATES WITH RIFAXIMIN MONOTHERAPY VERSUS LACTULOSE MONOTHERAPY
    Bajaj, Jasmohan
    Rahimi, Robert
    Allen, Christopher
    Heimanson, Zeev
    Israel, Robert
    Kowdley, Kris
    HEPATOLOGY, 2024, 80 : S1711 - S1711
  • [36] Rifaximin monotherapy has significantly reduced the risk of overt hepatic encephalopathy recurrence versus lactulose monotherapy in patients with cirrhosis and a history of previous episode (s): a post hoc analysis of randomized trials
    Bajaj, Jasmohan
    Rahimi, Robert
    Allen, Christopher
    Heimanson, Zeev
    Israel, Robert
    Kowdley, Kris V.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S212 - S213
  • [37] Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)
    Patel, V.
    Mcphail, M. J. W.
    Zamalloa, A.
    Stoy, S.
    Vijay, G. M.
    Huang, X.
    Rogers, G.
    Choo, J.
    Edwards, L.
    Gray, E.
    Woodhouse, C.
    Gencer, S.
    Coen, M.
    Wendon, J.
    Bruce, K.
    Shawcross, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S107 - S108
  • [38] Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Nastoupil, Loretta J.
    Rose, Adam C.
    Flowers, Christopher R.
    VALUE IN HEALTH, 2015, 18 (02) : 189 - 197
  • [39] Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation
    Kim, Su Ho
    Oh, Jung Suk
    Chun, Ho Jong
    Choi, Byung Gil
    Lee, Hae Giu
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (01) : 23 - 30
  • [40] A LIFE-LONG COST-EFFECTIVENESS MARKOV MODEL COMPARING HIGH-DOSE VERSUS STANDARD DOSE STATIN THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
    Plesnila-Frank, C.
    Asukai, Y.
    Ehlken, B.
    Giannitsis, E.
    Rieber, J.
    Berger, K.
    Mardekian, J.
    Rublee, D. A.
    VALUE IN HEALTH, 2009, 12 (03) : A146 - A147
12345